Flerie

Investment operations are led by CEO and Partner Ted Fjällman, who reports to Founder and Executive Chairman Thomas Eldered. Eldered co-founded Recipharm, the CDMO sold to EQT in 2021, and his pharmaceutical operating experience shapes the firm's investment posture. Flerie emphasizes active, long-term stewardship rather than passive capital allocation.

Flerie represents the reinvestment vehicle for wealth generated from Recipharm, which Eldered co-founded and later sold to EQT. The firm is not a single-family office but an investment company that takes public-company form as Flerie AB (publ), publishing quarterly interim reports. This listed structure imposes ongoing disclosure requirements uncommon among private family investment vehicles.

Yes. Flerie holds NorthX Biologics, a biomanufacturing facility located in Matfors, Sweden. This industrial asset complements the firm's financial portfolio and provides direct operational exposure to biologics production — a differentiator from most life-science investment firms that hold only financial stakes.

Flerie targets venture, growth-stage, and PIPE (private investment in public equity) transactions within the life-science sector. The firm has backed clinical-stage companies such as Prokarium, Mendus, and Lipum, indicating tolerance for development risk alongside later-stage public-market opportunities.

The firm leverages its leadership's pharmaceutical operating background and an extensive network of Key Opinion Leaders, including clinicians featured in its Flerie Insights podcast series. Industry association memberships — the European Healthcare Investor Association, British Venture Capital Association, and SwedenBIO — provide additional sourcing channels. Flerie differentiates itself by actively advancing portfolio companies' clinical pipelines through hands-on involvement rather than purely financial engineering.